Follow us on Twitter
twitter icon@FreshPatents


Uterine Fibroids patents

      

This page is updated frequently with new Uterine Fibroids-related patent applications.




 Selective androgen receptor degrader (sard) ligands and methods of use thereof patent thumbnailSelective androgen receptor degrader (sard) ligands and methods of use thereof
This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (ar-fl) including pathogenic and/or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation


 Methods of administering elagolix patent thumbnailMethods of administering elagolix
The present disclosure relates to the use of gnrh receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole..
Abbvie Inc.


 Selective androgen receptor degrader (sard) ligands and methods of use thereof patent thumbnailSelective androgen receptor degrader (sard) ligands and methods of use thereof
This invention provides novel 3-amino propanamide selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (ar-fl) including pathogenic or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation


 Selective androgen receptor degrader (sard) ligands and methods of use thereof patent thumbnailSelective androgen receptor degrader (sard) ligands and methods of use thereof
This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other ar-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (ar-fl) including pathogenic and/or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation


 System and  three-dimensional quantitative evaluaiton of uterine fibroids patent thumbnailSystem and three-dimensional quantitative evaluaiton of uterine fibroids
A system (100) and method which assess the results of uterine fibroid embolization. A fibroid lesion is three-dimensionally segmented by a segmentation module (110) on contrast-enhanced arterial phase mri or cbct images and a differentiation process performed by a subtraction module (114) identifies actual contrast enhancement from background enhancement.
Koninklijke Philips N.v.


 Surgical capture device and methods of use patent thumbnailSurgical capture device and methods of use
A surgical capture device is described that is configured to sequester tissue from a surgical cavity while the tissue is morcellated, or otherwise reduced in size. The capture device includes a side conduit that provides access to the interior of the device so that the tissue can be visualized during the morcellation process.
Espiner Medical Ltd.


 Progesteron receptor modulators for use in the therapy of uterine fibroids patent thumbnailProgesteron receptor modulators for use in the therapy of uterine fibroids
The present invention relates to a long-term therapy including repeated treatment courses of ulipristal acetate or any metabolite thereof for treating uterine fibroids. The present invention also relates to a combined therapy applying ulipristal acetate with a progestin in order to improve the currently used treatment for uterine fibroids..
Preglem Sa


 Method for treating uterine fibroids patent thumbnailMethod for treating uterine fibroids
The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-n,n-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


 Herbal composition and a  treating uterine fibroids patent thumbnailHerbal composition and a treating uterine fibroids
The invention discloses an herbal composition of treating uterine fibroid. The herbal composition comprises antrodia cinnamomea, astragalus membranaceus, and leonurus japonicus; wherein the weight percentages of antrodia cinnamomea, astragalus membranaceus and leonurus japonicus are 25 to 75%, 20.8 to 62.5% and 4.2 to 12.5% by weight of the formula, respectively.
Kang Li Biotech Co., Ltd.


 Fsh receptor antagonists patent thumbnailFsh receptor antagonists
Or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..

Modified release osmotic pump for ph-responsive drug delivery

In one aspect, the invention relates to controlled-release devices and methods of using same, alone or in combination with other agents, to deliver pharmaceutical agents, and more particularly to deliver birth control agent, fertility agents, hormone replacement agents, cervical ripening agents, agents to prevent a sexually transmitted disease, agents to treat a sexually transmitted disease, biologics, agents to treat a mucosal infection, agents to treat uterine fibroids, agents to treat reproductive cancers, agents to treat nausea gravidarum, and/or agents to treat endometriosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
University Of Utah Research Foundation

Methods and compositions for treating progesterone-dependent conditions

The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. Methods for treating these conditions are provided comprising systemically administering an antiprogestin and contemporaneously locally administering an antiprogestin.
Repros Therapeutics Inc.

Novel 19-nor-steroids and their use for treating progesterone- dependent conditions

The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. New compounds and methods for treating these conditions are disclosed.
Repros Therapeutics Inc.

Gonadotropin releasing hormone receptor antagonists, the preparation thereof and pharmaceutical composition comprising the same

Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as alzheimer disease.. .
Sk Chemicals Co., Ltd.

Bipolar coagulation probe and snare

An electrosurgical device that can be used to remove pedunculated tissue structures such as polyps and certain uterine fibroids includes bipolar surface electrodes and a bipolar snare. The device includes a probe having a proximal end and a distal end, bipolar surface electrodes adjacent to the distal end of the probe, and a bipolar snare extending distally from the distal end of the probe and including first and second snare electrodes.
Gyrus Acmi, Inc.

Method of thermal treatment for myolysis and destruction of benign uterine tumors

A high-power ultrasound heating applicator for minimally-invasive thermal treatment of uterine fibroids or myomas. High-intensity interstitial ultrasound, applied with minimally-invasive laparoscopic or hysteroscopic procedures, is used to effectively treat fibroids within the myometrium in lieu of major surgery.
The Regents Of The University Of California

Treatment of uterine fibroids by arterial ablation

Methods and apparatus for ablating blood vessels in treatment of uterine fibroids. A monopolar electrode provided on a needle probe is positioned in an artery supplying blood to a uterine fibroid.
Gyrus Acmi, Inc., D.b.a. Olympus Surgical Technologies America

Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (gnrh) receptor antagonists..

Organic compounds

Said compound is inhibitor of aldosterone synthase and aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase or aromatase. Accordingly, the compound of formula i can be used in treatment of hypokalemia, hypertension, congestive heart failure, atrial fibrillation, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome x, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, inflammation, increased formation of collagen, fibrosis such as cardiac or myocardiac fibrosis and remodeling following hypertension and endothelial dysfunction, gynecomastia, osteoporosis, prostate cancer, endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, infertility, fibrocystic breast disease, breast cancer and fibrocystic mastopathy.

Fsh receptor antagonists

The invention relates to fsh receptor antagonist according to general formula (i) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..

N-piperidin-4-yl derivatives

The invention relates to a n-piperidin-4-yl derivative having the general formula i or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same and to the use of said n-piperidin-4-yl derivatives for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, or for the treatment of uterine fibroids or other menstrual-related disorders.. .

Intrauterine system for use in medical treatment

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound.

Methods of treating heavy menstrual bleeding

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((r)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.. .

Treatment method and product for uterine fibroids using purified collagenase

The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.. .

Treatment method and product for uterine fibroids using purified collagenase

The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.. .

Fsh receptor antagonists

The invention relates to fsh receptor antagonist according to general formula i or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders..

Ultrasound based method and apparatus to determine the size of kidney stone fragments before removal via ureteroscopy

A transducer is used to send an ultrasound pulse toward a stone and to receive ultrasound reflections from the stone. The recorded time between a pulse that is reflected from the proximal surface and a pulse that is reflected either from the distal surface of the stone or from a surface supporting the stone is used to calculate the stone size.

Method for treating uterine fibroids

The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-n,n-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids..

Treatment of excessive menstrual bleeding associated with uterine fibroids

The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.. .

Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents

Wherein r1-r4 and x are as defined herein, pharmaceutical compositions including such compounds, and a method of treating a patient involving antagonizing the endogenous progesterone, such as in inducing menses and treating endometriosis, dysmenorrhea, endocrine hormone-dependent tumors, meningiomas, uterine leiomyomas, or uterine fibroids, inhibiting uterine endometrial proliferation, inducing cervical ripening, inducing labor, and in contraception.. .

Devices and methods for treating and/or preventing diseases

The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. A peptide such as leuprolide, via the vagina to a female mammal.

Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders

The present invention relates to the treatment of estrogen-dependent hyperproliferative uterine disorders including endometriosis, uterine fibroids, endometrial hyperplasia, uterine cancer, and their related symptoms by intravaginally administering at least two active agents selected from an aromatase inhibitor, an antiinflammatory agent, and a uterine-selective estrogen receptor antagonist. This combination therapy reduces local estrogen production, blocks local estrogen action, and suppresses inflammation locally, resulting in starvation of the estrogen-dependent diseased tissues, relief of related symptoms, and retardation of disease progression.

Catheter having radially expandable shaft

A catheter is disclosed, which is capable of delivering embolization beads for treating uterine fibroids. The elongate catheter shaft includes a radially expandable portion at its distal end, which can expand radially locally when an embolization bead passes through it.

Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational

A method and intravaginal drug delivery device for reducing size of a uterine fibroid in a female in need thereof are provided. The method includes administering intravaginally to the female a therapeutically effective amount of an active agent, wherein the agent is delivered on a delivery device directly to uterine fibroid, wherein said amount is able to significantly reduce the size of the uterine fibroid, wherein the active agent is any one of selective progesterone receptor modulator (sprm), an anti-progestin agent, and an anti-progestational agent..



Uterine Fibroids topics:
  • Uterine Fibroids
  • Endometriosis
  • Progesterone
  • Breast Cancer
  • Endometrial
  • Proliferation
  • Dysmenorrhea
  • Osteoporosis
  • Uterine Bleeding
  • Dysfunctional Uterine Bleeding
  • Dysfunction
  • Steoporosis
  • Prostate Cancer
  • Hyperplasia
  • Antagonist


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Uterine Fibroids for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Uterine Fibroids with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.352

    file did exist - 1765

    0 - 1 - 34